Persistence with denosumab therapy among osteoporotic women in the Canadian patient-support program

Current Medical Research and Opinion

Volumn 31, Issue 7, 2015, Pages 1391-1401

  Papaioannou, Alexandra ^a   Khan, Aliya ^a   Belanger, Andre ^b   Bensen, William ^a   Kendler, David ^c   Theoret, Francois ^b   Amin, Mo ^d   Brekke, Lee ^e   Erdmann, Michelle ^d   Walker, Valery ^e   Adachi, Jonathan D ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b Family Medicine   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d AMGEN INC   (United States)

^e OPTUM   (United States)

Author keywords

Database; Denosumab; Osteoporosis; Persistence; ProVital

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; PARATHYROID HORMONE[1-34]; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADULT; AGE; AGED; ARTICLE; CANADA; CANADIAN; DRUG WITHDRAWAL; FEMALE; FRAGILITY FRACTURE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PREDICTOR VARIABLE; PRIVATE HEALTH INSURANCE; RETROSPECTIVE STUDY; SELECTION BIAS; SELF REPORT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CANADA; DENOSUMAB; DIPHOSPHONATES; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; QUEBEC; RETROSPECTIVE STUDIES; TERIPARATIDE;

EID: 84934281744     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1053049     Document Type: Article

References (50)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 2001; 285: 785-95
2. Hanley DA, Josse RG. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. CMAJ 1996; 155: 921-3
3. Brown JP, Fortier M, Frame H, et al. Canadian Consensus Conference on osteoporosis, 2006 update. J Obstet Gynaecol Can 2006; 28(2 Suppl 1): S95-112
4. Cauley JA, Thompson DE, Ensrud KC, et al. Risk of mortality following clinical fractures. Osteoporos Int 2000; 11: 556-61
5. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353: 878-82
6. Gold DT. The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 1996; 18(3 Suppl): 185-9S
7. Ioannidis G, Papaioannou A, Hopman WM, et al. Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ 2009; 181: 265-71
8. Papaioannou A, Kennedy CC, Ioannidis G, et al. The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int 2009; 20: 703-14
9. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320-3
10. van Helden S, Cals J, Kessels F, et al. Risk of new clinical fractures within 2 years following a fracture. Osteoporos Int 2006; 17: 348-54
11. Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010; 182: 1864-73
12. Papaioannou A, Giangregorio L, Kvern B, et al. The osteoporosis care gap in Canada. BMC Musculoskelet Disord 2004; 5: 11
13. Silverman SL, Schousboe JT, Gold DT. Oral bisphosphonate compliance and persistence: a matter of choice?. Osteoporos Int 2011; 22: 21-6
14. Kothawala P, Badamgarav E, Ryu S, et al. Systematic review and metaanalysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 2007; 82: 1493-501
15. Drugcoverage.ca. A guide to reimbursement. Available at: http://www. drugcoverage.ca/en-ca/ [Last accessed February 2014]
16. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44-7
17. Imaz I, Zegarra P, González-Enríquez J, et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 2010; 21: 1943-51
18. Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009; 122(2 Suppl): S3-13
19. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81: 1013-22
20. McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004; 48: 271-87
21. Lee S, Glendenning P, Inderjeeth CA. Efficacy, side effects and route of administration are more important than frequency of dosing of antiosteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int 2011; 22: 741-53
22. Papaioannou A, Kennedy CC, Dolovich L, et al. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 2007; 24: 37-55
23. Gleeson T, Iversen MD, Avorn J, et al. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 2009; 20: 2127-34
24. Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 2006; 119(4 Suppl 1): S12-17
25. Cooper A, Drake J, Brankin E, et al. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006; 60: 896-905
26. Cook PF, Emiliozzi S, McCabe MM. Telephone counseling to improve osteoporosis treatment adherence: an effectiveness study in community practice settings. Am J Med Qual 2007; 22: 445-56
27. Waalen J, Bruning AL, Peters MJ, et al. A telephone-based intervention for increasing the use of osteoporosis medication: a randomized controlled trial. Am J Manag Care 2009; 15: e60-70
28. Miller PD. A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis 2011; 3: 271-82
29. Adler RA, Gill RS. Clinical utility of denosumab for treatment of bone loss in men and women. Clin Interv Aging 2011; 6: 119-24
30. Data on file. ProVital Program (#7115). Amgen Canada, 2014
31. Product Monograph: Prolia. Available at: http://www.amgen.ca/Prolia-PM. pdf [Last accessed April 2014]
32. Kendler DL, Macarios D, Lillestol MJ, et al. Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study. Menopause 2014; 21: 25-32
33. Freemantle N, Satram-Hoang S, Tang ET, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 2012; 23: 317-26
34. Kendler DL, McClung MR, Freemantle N, et al. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 2011; 22: 1725-35
35. Karlsson L, Lundkvist J, Intorcia M, et al. Treatment persistence in Swedish women initiating denosumab treatment for postmenopausal osteoporosis. Abstract presented at: ISPOR 16th Annual European Congress. Dublin, Ireland, 2-6 November 2013
36. Silverman S, Siris E, Kendler DL, et al. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporos Int 2015; 26: 361-72
37. Burden AM, Tadrous M, Wong L, et al. Shiny and new: uptake and persistence with non-oral osteoporosis medications in Ontario, Canada. Abstract presented at: WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. Seville, Spain, 2-5 April 2014
38. Silverman SL, Nasser K, Nattrass S, et al. Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial. Osteoporos Int 2012; 23: 1069-74
39. Burden AM, Paterson JM, Solomon DH, et al. Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporos Int 2012; 23: 1075-82
40. Ziller V, Kostev K, Kyvernitakis I, et al. Persistence and compliance of medications used in the treatment of osteoporosis - analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Ther 2012; 50: 315-22
41. Audran M, Jakob FJ, Palacios S, et al. A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years. Rheumatol Int 2013; 33: 2231-9
42. Nogues X, Luz Rentero M, Rodríguez AL. Use of an educational support program to assist patients receiving injectable osteoporosis treatment: experience with teriparatide. Curr Med Res Opin 2014; 30: 287-96
43. Briot K, Ravaud P, Dargent-Molina P, et al. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int 2009; 20: 625-30
44. Stuurman-Bieze AG, Hiddink EG, van Boven JF, et al. Proactive pharmaceutical care interventions decrease patients' nonadherence to osteoporosis medication. Osteoporos Int 2014; 25: 1807-12
45. Lai PS, Chua SS, Chew YY, et al. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women. J Clin Pharm Ther 2011; 36: 557-67
46. CNW. Women in Quebec now have ccess to Prolia (denosumab) for postmenopausal osteoporosis. Available at: http://www.newswire.ca/en/ story/809807/women-in-quebec-now-have-access-To-prolia-denosumabfor- postmenopausal-osteoporosis [Last accessed ebruary 2014]
47. CNW. Women in Ontario now have access to Prolia (denosumab) for postmenopausal osteoporosis. vailable at: http://www.newswire.ca/en/story/929571/women-in-ontario-now-have-access-To-prolia-denosumab-forpostmenopausal-osteoporosis [Last accessed February 2014]
48. Penning-van Beest FJ, Goettsch WG, Erkens JA, et al. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 2006; 28: 236-42
49. Carr AJ, Thompson PW, Cooper C. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 2006; 17: 1638-44
50. Jones TJ, Petrella RJ, Crilly R. Determinants of persistence with weekly bisphosphonates in patients with osteoporosis. J Rheumatol 2008; 35: 1865-73